CG Oncology, Inc. is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. The product candidate is designed as a bladder-sparing therapy for patients with non-muscle invasive bladder cancer (NMIBC), targeting high-risk BCG-unresponsive, BCG-exposed, BCG-naïve, and intermediate-risk populations. Cretostimogene operates through a dual mechanism of action, eliminating cancer cells via selective replication and activating an anti-tumor immune response. It is administered intravesically, a route similar to standard-of-care Bacillus Calmette-Guérin (BCG) therapy. The company is conducting Phase 3 clinical trials, including BOND-003 and PIVOT-006, as well as Phase 2 trials such as CORE-008, to evaluate the safety and efficacy of cretostimogene as a monotherapy and in combination with other agents like pembrolizumab and gemcitabine. CG Oncology has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration for its lead indication. The company provides a backbone therapy option for patients who currently face radical cystectomy or have limited treatment options due to BCG shortages or resistance.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage cgoncology.com
Sector Healthcare IR page cgoncology.com/news-media/cg-oncology-to-present-at-upcoming-investor-conferences-in-june
Tags
bladder cancer, oncolytic immunotherapy, non-muscle invasive bladder cancer, intravesical therapy, bcg-unresponsive, urologic oncology, clinical stage, immunotherapy, cretostimogene grenadenorepvec, cretostimogene, BOND-003, PIVOT-006, CORE-008, CORE-001, pembrolizumab, gemcitabine, Bacillus Calmette-Guérin, BCG
Press page cgoncology.com/news-media

Metrics

Valuation  
Market cap $ 7.083B
Market cap (USD) $ 7.083B
P/E -28.63
PEG —
P/BV 7.15
P/S —
P/OCF -37.82
P/FCF -37.44
Dividend yield —
Turnover / mcap —
Returns  
ROE -21.7%
ROI -21.3%
ROIC -18.9%
Profit margin -3,985.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 0.30%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 18
Quality score -43.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 4.04M 1.139M 204K 191K 10.358M
Net profit -160.995M -88.039M -48.607M -35.443M -12.839M
Free cash flow -132.48M -78.947M -45.679M -29.818M -13.751M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 41.52 28.68 — — —
Price performance 12m 0.45 — — — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 0.00 688,000
Borrowings, non-current (USD) — — 0.00 3M
Lease liabilities (USD) — 461,000 238,000 4.02M
Cash and deposits (USD) 88.1M 8.27M 257M 32.5M
Intangible assets (USD) — — 0.00 575,000
Right-of-use assets (USD) — 422,000 221,000 3.97M
Net debt (borrowings + leases - cash) (USD) — — -257M -25.5M
Cash flow detail
Operating cash flow (USD) — -45.7M -78.7M -132M
Purchases of property, plant and equipment (USD) — — -234,000 -134,000
Change in receivables (cash effect) (USD) — — — -320,000
Change in inventories (cash effect) (USD) — — — -444,000
Change in payables (cash effect) (USD) — 2.01M 3.28M -1.64M
Interest paid (cash effect) (USD) — -376,000 — -103,000
Income taxes paid (cash effect) (USD) — — — -16,000
Share-based compensation (USD) — 1.53M 11.4M 26.7M
Operating cash flow before change in receivables (USD) — — — -132M
Free cash flow (OCF - PPE - intangibles) (USD) — — -78.9M -132M
Income detail
Research and development expense (USD) — 45.8M 82.1M 117M
Reported May 9, 2024 Mar 28, 2025 Nov 14, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

-Cretostimogene reduced the risk of recurrence by 68%, demonstrating a statistically significant and clinically meaningful benefit with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001)

-Compelling safety and tolerability results, no Grade 3 or higher TRAEs and no treatment-related discontinuations

-PIVOT-006 topline results to be presented as a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting on December 2, 2026

-PIVOT-006 data will support a second BLA submission in intermediate-risk and high-grade Ta NMIBC anticipated in Q2 2027

-Based on FDA feedback, initial BLA submission in BCG-unresponsive NMIBC to be broadened to include both CIS and high-grade papillary-only disease; completion anticipated in March 2027

Dallas, TX, November 16, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced positive topline results from PIVOT-006, its Phase 3 registrational trial evaluating adjuvant intravesical cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC, following complete tumor resection. There are currently no U.S.

Nov 06, 2026

PDF Version

  • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026

  • BOND-003 Cohort P and CORE-008 Cohort CX 12-month data anticipated December 2026

  • BLA completion for BCG-unresponsive NMIBC anticipated Q4 2026

  • Well-positioned to deliver on key milestones with approximately $984.5 million of cash, cash equivalents and marketable securities sufficient to fund operations through 2029

DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.

“We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December, which further strengthens the growing body of evidence for cretostimogene across the NMIBC landscape and supports our goal to address the broadest number of patients. We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders,” stated Arthur Kuan, Chairman, President & Chief Executive Officer at CG Oncology.

Corporate Highlights

  • Strengthened Executive Leadership Team with the addition of life-science executive Isabel Kalofonos as Chief Commercial Officer

  • In October, the Company appointed Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos brings more than 20 years of experience driving successful launches including PALSONIFYTM (paltusotine) and ELAHERE® (mirvetuximab soravtansine) through strong commercial execution, helping bring innovative therapies to patients at scale across the biotechnology and pharmaceutical industries.

Anticipated 2026 Milestones

  • PIVOT-006 (intermediate-risk and high-grade Ta ≤ 3cm NMIBC): Phase 3 topline data November 2026

  • CORE-008 Cohort CX (BCG-exposed HR and BCG-unresponsive NMIBC) 12-month data December 2026

  • BOND-003 Cohort P (BCG-unresponsive papillary only NMIBC) 12-month data December 2026

  • Completion of BLA submission in initial indication of BCG-unresponsive NMIBC with CIS with or without papillary disease Q4 2026

Third Quarter Financial Highlights

  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2026 were $984.5 million, compared with $1.0 billion as of June 30, 2026. The Company anticipates its existing cash, cash equivalents and marketable securities as of this date will be sufficient to fund operations through 2029.

  • Research and Development (R&D) Expenses: R&D expenses were $39.2 million for the third quarter of 2026, as compared to $27.9 million for the prior year period. The increase was primarily due to an increase in clinical trial expenses, including CMC costs, and an increase in compensation costs due to increased headcount.

  • General and Administrative (G&A) Expenses: G&A expenses were $23.0 million for the third quarter of 2026, as compared to $23.3 million for the prior year period. The decrease was primarily due to a decrease in professional and consultant fees, partially offset by an increase in personnel-related expenses, including compensation costs from increased headcount, and an increase in other general G&A expenses.

  • Net Loss: Net loss was $56.9 million, or $(0.64) per share, for the third quarter of 2026, as compared to a net loss of $43.8 million, or $(0.57) per share, for the prior year period.

About Cretostimogene Grenadenorepvec

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 700 patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program includes two Phase 3 clinical trials: BOND-003 for BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk and high-grade Ta ≤ 3cm NMIBC. Cretostimogene has received FDA Fast Track and Breakthrough Therapy designations for BCG-unresponsive NMIBC. CG Oncology also has a multi-cohort trial, CORE-008, evaluating the safety and efficacy of cretostimogene in BCG-exposed HR and BCG-unresponsive NMIBC. Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements. Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.

About CG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Forward-Looking Statements

CG Oncology cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding our anticipated cash runway; our future results of operations and financial position; the timing, progress, conduct and completion of our ongoing and planned clinical trials and preclinical studies of cretostimogene; the timing, availability, announcement, presentation and results of clinical data, including topline data from PIVOT-006 and 12-month data from BOND-003 Cohort P and CORE-008 Cohort CX; anticipated milestones in our development pipeline; the timing, completion, acceptance, review and outcome of regulatory filings and submissions for cretostimogene, including the anticipated completion of our BLA submission for BCG-unresponsive NMIBC; the timing or likelihood of regulatory approvals and the scope of any approved indication or product label; the potential safety, efficacy, therapeutic benefits, clinical utility, commercial potential and market opportunity of cretostimogene for patients with BCG-unresponsive, BCG-exposed, intermediate-risk and high-grade Ta NMIBC; and the potential for cretostimogene to address a broad range of NMIBC patients or become a backbone therapy. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline, preliminary, interim or 12-month clinical-trial results may not be complete, may differ from final results, may not be confirmed upon full analysis of the data, and may not predict future or longer-term results; data from one trial, patient population, cohort or time point may not be predictive of results from other trials, populations, cohorts or time points; potential delays in the commencement, enrollment, conduct or completion of clinical trials, including the BOND-003, PIVOT-006 and CORE-008 trials; potential delays in the completion, submission, acceptance or review of our BLA, and the possibility that the FDA may not approve cretostimogene on the anticipated timeline, for the anticipated indication or label, or at all; we may use our capital resources sooner than expected, and our existing capital resources may be insufficient to achieve our anticipated milestones or fund operations for the period anticipated; our cash-runway estimates are based on assumptions regarding our current operating plans, expenses and capital requirements that may prove to be incorrect or may change; our dependence on third parties in connection with manufacturing, shipping, clinical and preclinical testing activities; results from earlier clinical trials and preclinical studies may not be predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene may limit or prevent its development, regulatory approval or commercialization; we may be unable to successfully develop, obtain approval for, manufacture or commercialize cretostimogene; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K and other filings that we make with the SEC from time to time (which are available at http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Listen to this article now

DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than 20 years of commercial leadership experience, Ms. Kalofonos will lead the Company’s commercial strategy and execution as CG Oncology advances toward the potential launch of cretostimogene grenadenorepvec and continues to establish itself as a leader in bladder cancer.

“Isabel’s appointment reflects our commitment to ensuring we are well positioned to bring cretostimogene to as many patients as possible upon approval,” said Arthur Kuan, Chairman and Chief Executive Officer of CG Oncology. “As we prepare for a potential first commercial launch, we are making deliberate investments in experienced leaders who have successfully built commercial organizations, developed differentiated strategies, and delivered product launches at scale. Isabel brings an outstanding track record of commercial execution across multiple therapeutic areas and stages of growth, and we are confident her expertise will be instrumental as we prepare to deliver on the full potential of cretostimogene.”

Ms. Kalofonos brings more than 20 years of experience driving successful launches and commercial execution, helping bring innovative therapies to patients at scale across the biotechnology and pharmaceutical industries. Most recently, she served as Chief Commercial Officer of Crinetics Pharmaceuticals (acquired by Vertex Pharmaceuticals), where she played a key role in the company’s transition to the commercial stage, helping to drive the successful launch of PALSONIFY™ (paltusotine) and advance commercial planning across the pipeline.

Prior to Crinetics, Ms. Kalofonos served as Chief Commercial Officer at ImmunoGen (acquired by AbbVie), where she led the successful launch of ELAHERE® (mirvetuximab soravtansine) in ovarian cancer. Earlier in her career, Ms. Kalofonos served as Senior Vice President and Global Head of the Prescription Business Unit at Galderma, where she oversaw the build-out of the business unit and pre-launch preparations for NEMLUVIO® (nemolizumab). She also served as Vice President and Head of the Hereditary Angioedema Franchise at Takeda Pharmaceuticals (formerly Shire), leading a multi-billion-dollar business and the successful global launch of TAKHZYRO® (lanadelumab‑flyo). Throughout her career, she has built and led high-performing global commercial organizations across oncology, immunology, rare diseases, and neurology. Ms. Kalofonos holds an M.B.A. in Entrepreneurship and Marketing from Babson College and a bachelor’s degree in Industrial Engineering from Pontificia Universidad Javeriana.

“CG Oncology is entering an exciting and transformative period, and I am thrilled to join the company at such a pivotal time,” said Isabel Kalofonos. “The clinical data generated to date for cretostimogene, the significant unmet need that remains for patients with bladder cancer, and the passion of the CG Oncology team make this a truly compelling opportunity. Having spent much of my career preparing companies for launch and building commercial organizations, I look forward to hitting the ground running, partnering across the organization, and helping ensure we are ready to successfully bring cretostimogene to patients.”

About Cretostimogene Grenadenorepvec
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 400 patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program includes two Phase 3 clinical trials: BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC. Cretostimogene has received FDA Fast Track and Breakthrough Therapy designations. CG Oncology also has a Phase 2 trial, CORE-008, evaluating the safety and efficacy of cretostimogene in high-risk NMIBC. Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements. Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.

About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com .

Forward-Looking Statements
CG Oncology cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding the potential approval and commercial launch of cretostimogene, the timing, progress and success of our commercial launch preparations and commercialization activities, our ability to build and execute our commercial strategy and establish the infrastructure necessary to support a potential commercial launch, the anticipated contributions of our Chief Commercial Officer, our ability to bring cretostimogene to patients, if approved, the potential therapeutic and commercial benefits of cretostimogene, and our ability to advance our position in the treatment of bladder cancer. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: the timing and outcome of regulatory review of cretostimogene and the possibility that regulatory approval may be delayed, limited or not obtained, uncertainties regarding the timing and success of our commercial launch preparations and commercialization activities, our ability to establish, scale and maintain an effective commercial infrastructure, the scope of any approved indication or labeling for cretostimogene, the rate and degree of market acceptance of cretostimogene, if approved, by patients, healthcare providers and payors, our ability to obtain and maintain adequate pricing, coverage and reimbursement, our ability and the ability of our third-party manufacturers and suppliers to manufacture and supply sufficient quantities of cretostimogene for commercial use, competition from existing and future therapies, unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval or commercialization, our dependence on third parties in connection with manufacturing, shipping, clinical testing and commercialization activities, our ability to attract and retain key personnel, and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K and other filings that we make with the SEC from time to time (which are available at https://www.sec.gov ). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Prompts

CG Oncology, Inc. (ticker CGON), listed in United States.

ETFs Holding CG Oncology, Inc.

ETF Weight in ETF Shares Market value As of
CANC 2.76% 77,547 $ 5.828M Aug 31, 2026
TMED 0.62% 1,996 $ 141.816K Jun 30, 2026
FMED 0.41% 2,800 $ 210.448K Aug 31, 2026
FSCC 0.39% 18,787 $ 1.412M Aug 31, 2026
GDOC 0.37% 960 $ 72.154K Aug 31, 2026
FTKI 0.35% 1,038 $ 88.002K Nov 16, 2026
ESSC 0.28% 1,408 $ 100.236K Jul 31, 2026
TCAF 0.28% 353,549 $ 29.974M Nov 17, 2026
FSEG 0.26% 208 $ 14.778K Jun 30, 2026
RUSC 0.25% 2,811 $ 199.722K Jun 30, 2026
FFSM 0.25% 51,700 $ 3.681M Jul 31, 2026
SEIS 0.24% 19,944 $ 1.417M Jun 30, 2026
TMSL 0.20% 75,322 $ 5.352M Jun 30, 2026
CLSE short -0.19% -22,345 $ -1.679M Aug 31, 2026
VFMO 0.16% 40,850 $ 3.07M Aug 31, 2026
RESM 0.13% 67 $ 4,760.35 Jun 30, 2026
ESUM 0.09% 2,423 $ 172.493K Jul 31, 2026
AVIE 0.07% 130 $ 11.021K Nov 16, 2026
FESM 0.07% 53,679 $ 3.814M Jun 30, 2026
MSSM 0.03% 2,727 $ 204.961K Aug 31, 2026
DFAS 0.02% 113,428 $ 7.957M Nov 12, 2026
DFAU 0.01% 13,756 $ 964.983K Nov 12, 2026
DFAC 0.01% 63,207 $ 4.434M Nov 12, 2026
DFUS 0.00% 7,388 $ 518.268K Nov 12, 2026
DCOR 0.00% 4,156 $ 291.543K Nov 12, 2026
NTRL short 0.00% -713 $ 0.00 Nov 16, 2026